Skip to main content
. 2022 Mar 28;13(3):272. doi: 10.1038/s41419-022-04620-3

Fig. 7. Schematic diagram of the mechanism by which Bev affects osteosarcoma cell proliferation and angiogenesis.

Fig. 7

Serum-EVs deliver MIAT to osteosarcoma cells. Bev can inhibit the expression of MIAT in osteosarcoma cells and upregulate the expression of miR-613. miR-613 targets GPR158 and inhibits its mRNA and protein expression, thereby inhibiting the proliferation and angiogenesis of osteosarcoma cells.